Advertisement
ORMP vs TSHA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a Hold and TSHA is a Hold.
ORMP's RSI Indicator recovers from oversold territory
The RSI Oscillator for ORMP moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for ORMP turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 41 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ORMP entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.498). P/E Ratio (0.910) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.259) settles around the average of (130.981) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
TSHA's RSI Indicator ascends from oversold territory
The RSI Indicator for TSHA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 33 of the 35 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TSHA just turned positive on October 21, 2026. Looking at past instances where TSHA's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Following a +6.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSHA advanced for three days, in 213 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TSHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 53 cases where TSHA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TSHA as a result. In 69 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The 50-day moving average for TSHA moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for TSHA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.643) is normal, around the industry mean (3.498). P/E Ratio (-10.561) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. TSHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TSHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ORMP | TSHA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 21 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 15 | 98 | |
PRICE GROWTH RATING 1..100 | 49 | 59 | |
P/E GROWTH RATING 1..100 | 94 | 19 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TSHA's Valuation (21) in the null industry is somewhat better than the same rating for ORMP (67) in the Pharmaceuticals Other industry. This means that TSHA’s stock grew somewhat faster than ORMP’s over the last 12 months.
TSHA's Profit vs Risk Rating (100) in the null industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that TSHA’s stock grew similarly to ORMP’s over the last 12 months.
ORMP's SMR Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for TSHA (98) in the null industry. This means that ORMP’s stock grew significantly faster than TSHA’s over the last 12 months.
ORMP's Price Growth Rating (49) in the Pharmaceuticals Other industry is in the same range as TSHA (59) in the null industry. This means that ORMP’s stock grew similarly to TSHA’s over the last 12 months.
TSHA's P/E Growth Rating (19) in the null industry is significantly better than the same rating for ORMP (94) in the Pharmaceuticals Other industry. This means that TSHA’s stock grew significantly faster than ORMP’s over the last 12 months.
| ORMP | TSHA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 71% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 80% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 79% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 83% |
| Advances ODDS (%) | N/A | 6 days ago 82% |
| Declines ODDS (%) | 1 day ago 81% | 1 day ago 89% |
| BollingerBands ODDS (%) | 1 day ago 84% | 4 days ago 83% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ORMP’s FA Score shows that 1 FA rating(s) are green while TSHA’s FA Score has 2 green FA rating(s).
- ORMP’s FA Score: 1 green, 4 red.
- TSHA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ORMP’s TA Score shows that 3 TA indicator(s) are bullish while TSHA’s TA Score has 4 bullish TA indicator(s).
- ORMP’s TA Score: 3 bullish, 4 bearish.
- TSHA’s TA Score: 4 bullish, 5 bearish.
Price Growth
ORMP (@Biotechnology) experienced а -3.89% price change this week, while TSHA (@Biotechnology) price change was -5.31% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
ORMP is expected to report earnings on Mar 03, 2027.
TSHA is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ORMP and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with DRTS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then DRTS could also see price increases.
| Ticker / NAME | Correlation To ORMP | 1D Price Change % | ||
|---|---|---|---|---|
| ORMP | 100% | -7.94% | ||
| DRTS - ORMP | 52% Loosely correlated | +0.15% | ||
| INO - ORMP | 44% Loosely correlated | -2.05% | ||
| MBIO - ORMP | 44% Loosely correlated | +0.90% | ||
| CGEM - ORMP | 42% Loosely correlated | +0.88% | ||
| MCRB - ORMP | 41% Loosely correlated | -0.71% | ||
More | ||||
TSHA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TSHA has been loosely correlated with SLDB. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if TSHA jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To TSHA | 1D Price Change % | ||
|---|---|---|---|---|
| TSHA | 100% | -2.61% | ||
| SLDB - TSHA | 54% Loosely correlated | -2.29% | ||
| STOK - TSHA | 51% Loosely correlated | +1.83% | ||
| BNTC - TSHA | 51% Loosely correlated | -0.55% | ||
| FDMT - TSHA | 51% Loosely correlated | +0.95% | ||
| KYTX - TSHA | 51% Loosely correlated | +0.40% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FXP | 22.65 | 0.19 | +0.86% |
| ProShares UltraShort FTSE China 50 (FXP) | |||
| IAF | 12.35 | 0.03 | +0.24% |
| abrdn Australia Equity Fund | |||
| TUA | 19.13 | 0.02 | +0.10% |
| Simplify Short Term Treasury Futures Strategy ETF (TUA) | |||
| FTBD | 47.06 | -0.08 | -0.16% |
| Fidelity Tactical Bond ETF (FTBD) | |||
| VRP | 23.55 | -0.08 | -0.34% |
| Invesco Variable Rate Preferred ETF (VRP) | |||